Molecular Mechanisms of Resistance to Tamoxifen Therapy in Breast Cancer

Abstract
Clinical data suggest that the use of adjuvant tamoxifen citrate (Nolvadex) for a minimum of 5 years, and possibly indefinitely, will result in maximal antitumor benefit. There is concern that long-term tamoxifen maintenance therapy may result in the induction of drug resistance. This article reviews the potential molecular mechanisms of resistance to tamoxifen and explores the possibility of tamoxifen-stimulated tumor growth. (Arch Surg. 1993;128:1187-1191)

This publication has 1 reference indexed in Scilit: